Provided by Tiger Trade Technology Pte. Ltd.

Rhythm Pharmaceuticals Inc.

93.41
-1.8050-1.90%
Post-market: 93.410.00000.00%19:30 EDT
Volume:850.61K
Turnover:80.40M
Market Cap:6.43B
PE:-29.97
High:96.48
Open:95.34
Low:93.00
Close:95.22
52wk High:122.20
52wk Low:74.50
Shares:68.85M
Float Shares:65.39M
Volume Ratio:1.05
T/O Rate:1.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1172
EPS(LYR):-3.1100
ROE:-117.04%
ROA:-30.96%
PB:62.45
PE(LYR):-30.04

Loading ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 05

Rhythm Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 04

Rhythm Pharma's Obesity Drug Shows Promise for Brain Tumor-Related Weight Condition

Reuters
·
Aug 04

Palvella Therapeutics Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 04

Stock Track | Rhythm Pharmaceuticals Soars 5.58% in Pre-market on Q2 Earnings Beat and Positive Phase 2 RM-718 Data

Stock Track
·
Aug 04

Rhythm Pharma Q2 FY26 Net Loss Widens to $50.4 Million; Revenue Rises 47% to $71.3 Million

Reuters
·
Aug 04

Rhythm Pharmaceuticals Q2 EPS $(0.73) Beats $(0.82) Estimate, Sales $71.255M Beat $67.277M Estimate

Benzinga Earnings
·
Aug 04

Earnings Flash (RYTM) Rhythm Pharmaceuticals Posts Q2 Net Loss $0.73 a Share, vs. FactSet Est of $0.83 Loss

MT Newswires Live
·
Aug 04

Rhythm Pharmaceuticals Q2 Net Income USD -49.298 Million Vs. IBES Estimate USD -55.5 Million

Reuters
·
Aug 04

Rhythm Pharmaceuticals Q2 Basic EPS USD -0.73

THOMSON REUTERS
·
Aug 04

Rhythm Pharmaceuticals - Estimates Non-Gaap Operating Expenses $363 Mln-$397 Mln for Year Ending Dec 31, 2026

THOMSON REUTERS
·
Aug 04

Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial That Showed Rm-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity

THOMSON REUTERS
·
Aug 04

Rhythm Pharmaceuticals - Two Participants Discontinued Rm-718 Treatment Due to Adverse Events

THOMSON REUTERS
·
Aug 04

Rhythm Pharmaceuticals - Reports 11.6% Mean Bmi Reduction at Week 16 in Phase 2 Rm-718 Trial

THOMSON REUTERS
·
Aug 04

Rhythm Pharmaceuticals - Rm-718 Generally Well Tolerated with Most Common Adverse Events Injection Site Reactions, Nausea, Vomiting

THOMSON REUTERS
·
Aug 04

Rhythm Pharmaceuticals - Reports Two Mild Cases of Injection Site Hyperpigmentation in Rm-718 Trial

THOMSON REUTERS
·
Aug 04

Rhythm Pharmaceuticals - Eight Patients Remain on Active Treatment as of July 16, 2026

THOMSON REUTERS
·
Aug 04

Earning Preview: Rhythm Pharmaceuticals Inc. Q2 revenue is expected to increase by 54.19%, and institutional views are bullish

Earnings Agent
·
Jul 29

Rhythm Pharmaceuticals (RYTM) Faces A Big Undervaluation Call, Is The Upside Already Priced In?

Simply Wall St.
·
Jul 27

Wells Fargo Releases a Buy Rating on Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
Jul 16